Astrazeneca (AZN) Operating Income (2009 - 2026)
Astrazeneca (AZN) posted quarterly Operating Income of $3.2 billion for Q2 2026, down 9.81% year-over-year from $3.5 billion in Q2 2025, and down 25.48% quarter-over-quarter from $4.2 billion in Q1 2026.
Astrazeneca (AZN) Operating Income (2009 - 2026) Analysis & Trends
Astrazeneca's Operating Income history runs 18 years deep, the most recent figure standing at $3.2 billion for Q2 2026.
- In Q2 2026, Operating Income fell 9.81% year-over-year to $3.2 billion; the TTM figure through Jun 2026 stood at $14.0 billion (up 23.38% YoY), while the FY2025 annual figure was $13.7 billion, up 37.39% from the prior year.
- Operating Income for Q2 2026 stood at $3.2 billion, down from $4.2 billion in the prior quarter.
- The five-year high for Operating Income was $7.0 billion in Q4 2023, with the low at $539.0 million in Q2 2022.
- The 5-year median for Operating Income is $2.7 billion (2022), against an average of $2.8 billion.
- The sharpest annual moves came in 2022 and 2024: Operating Income jumped 1011.99% in 2022, then slumped 70.74% in 2024.
- Astrazeneca's Operating Income stood at $2.7 billion in 2022, then soared by 161.32% to $7.0 billion in 2023, then plunged by 70.74% to $2.0 billion in 2024, then surged by 46.27% to $3.0 billion in 2025, then gained by 6.25% to $3.2 billion in 2026.
- Business Quant data shows AZN's Operating Income at $3.2 billion in Q2 2026, $4.2 billion in Q1 2026, and $3.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.16 Bn |
| Mar 31, 2026 | 4.25 Bn |
| Dec 31, 2025 | 2.98 Bn |
| Sep 30, 2025 | 3.58 Bn |
| Jun 30, 2025 | 3.51 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 2.04 Bn |
| Sep 30, 2024 | 2.11 Bn |
| Jun 30, 2024 | 2.75 Bn |
| Mar 31, 2024 | 3.12 Bn |
| Dec 31, 2023 | 6.96 Bn |
| Sep 30, 2023 | 1.95 Bn |
| Jun 30, 2023 | 2.46 Bn |
| Mar 31, 2023 | 2.55 Bn |
| Dec 31, 2022 | 2.66 Bn |
| Sep 30, 2022 | 1.25 Bn |
| Jun 30, 2022 | 539.00 Mn |
| Mar 31, 2022 | 878.00 Mn |
| Dec 31, 2021 | -292.00 Mn |
| Sep 30, 2021 | -1.67 Bn |